| abstract |
ABSTRACT OF THE DISCLOSURE Antibody complexes comprising hapten-modified diagnostic or therapeutic agents and anti-hapten antibodies are disclosed. Administration of hapten-modified agents such as p-bromoacetamidobenzyl EDTA(BABE)-CL232,468, BABE-Co Bleomycin and the indium complex of p-isothiocyanobenzyl EDTA linked to mitomycin C, complexed with suitable anti-hapten antibodies, extends the serum half-life and permit an increased concentration of such diagnostic or therapeutic agents at in vivo target sites. |